Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Abstract

(6%), 21 (46%), 7 (15%) and 15 (33%) for T1, T2, T3 and T4, respectively. Treatment consisted in a transurethral resection of bladder tumor as complete as feasible followed by curative concurrent chemoradiation. Results:Twenty-nine patients showed complete response (CR), 22 of whom (48%) had a continuously tumor free bladder. With a median follow-up of 30 months (12-92 months), the 3-year overall survival (OS) was 50%; Local recurrence-free survival (LRFS) was 59% at 3 years and the distant metastases free survival (MFS) was